<p>Bengaluru: A large-scale, first-of-its-kind national trial is underway to test the efficacy of a drug treatment for cardiovascular diseases such as coronary heart disease and strokes.</p><p>The Indian Council of Medical Research's (ICMR) Centre for Advanced Research (CAR) at St John's Research Institute has launched India’s largest cardiovascular disease prevention trial, ICRAG-2, which evaluates a low-cost, multi-pronged intervention for cardiovascular diseases (CVD).</p><p>ICRAG-2 is led by Dr Denis Xavier, Professor and Head of the Department of Pharmacology and Division of Clinical Research and Training at St John’s Medical College and Research Institute.</p> .<p>Over the next three years, the trial will be conducted at 40 sites across the country, centrally coordinated at St John’s, with support from four Regional Coordinating Centres — AIIMS Bhopal, JIPMER Puducherry, SRM Chennai, and Assam Medical College, Dibrugarh. It will assess outcomes including heart attacks, strokes, CVD-related hospitalisations and deaths, aiming to develop a low-cost model for the treatment and prevention of CVDs in India.</p><p>The trial will evaluate the efficacy of a rational fixed-dose combination (FDC), mobile health (mHealth), and a non-physician health worker-led strategy for heart disease and stroke prevention.</p> .<p>On Monday, the institute inaugurated a training programme for national investigators, coordinators, and non-physician health workers (NPHWs), which will continue until Friday.</p><p>Researchers note that the findings will provide robust, data-backed evidence to reduce risk factors and improve cardiovascular disease care in India and other low- and middle-income countries.</p>
<p>Bengaluru: A large-scale, first-of-its-kind national trial is underway to test the efficacy of a drug treatment for cardiovascular diseases such as coronary heart disease and strokes.</p><p>The Indian Council of Medical Research's (ICMR) Centre for Advanced Research (CAR) at St John's Research Institute has launched India’s largest cardiovascular disease prevention trial, ICRAG-2, which evaluates a low-cost, multi-pronged intervention for cardiovascular diseases (CVD).</p><p>ICRAG-2 is led by Dr Denis Xavier, Professor and Head of the Department of Pharmacology and Division of Clinical Research and Training at St John’s Medical College and Research Institute.</p> .<p>Over the next three years, the trial will be conducted at 40 sites across the country, centrally coordinated at St John’s, with support from four Regional Coordinating Centres — AIIMS Bhopal, JIPMER Puducherry, SRM Chennai, and Assam Medical College, Dibrugarh. It will assess outcomes including heart attacks, strokes, CVD-related hospitalisations and deaths, aiming to develop a low-cost model for the treatment and prevention of CVDs in India.</p><p>The trial will evaluate the efficacy of a rational fixed-dose combination (FDC), mobile health (mHealth), and a non-physician health worker-led strategy for heart disease and stroke prevention.</p> .<p>On Monday, the institute inaugurated a training programme for national investigators, coordinators, and non-physician health workers (NPHWs), which will continue until Friday.</p><p>Researchers note that the findings will provide robust, data-backed evidence to reduce risk factors and improve cardiovascular disease care in India and other low- and middle-income countries.</p>
